This isn't a very clear cut data set.
However, it isn't doom n gloom. rather, they showed a significant effect on non-inflammatory lesions in both cohorts. the secondary data readout.
If just looking at the AUS data, there's a significant effect in both inflammatory and non-inflammatory lesions.
They need to clarify the placebo and vehicle, I don't really understand how a placebo effect can be so substantial.
safety profile is good.
it works. just not as well in inflammatory lesions as we may have hoped across both Australian and American cohorts.....
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-195
-
- There are more pages in this discussion • 208 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.020(5.48%) |
Mkt cap ! $543.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 34.0¢ | $4.566M | 13.13M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 410003 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 346713 | 8 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |